SCHEMBL8286409

SCHEMBL8286409

COC(=O)c1cc(B2OC(C)(C)C(C)(C)O2)cc2c1OC(c1ccccc1)(c1ccccc1)O2

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 3/20 0.35
LPL P06858 2/20 0.35
P4HB P07237 1/20 0.35
CNR1 P21554 6/20 0.34
DGAT1 O75907 1/20 0.34
KDM4E B2RXH2 2/20 0.33
PDGFRB P09619 1/20 0.33
KDR P35968 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ALOX5 P09917 1/20 0.32
PDE4B Q07343 1/20 0.32
LMNA P02545 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868406 0.79 KDM4E (0.42) CNR1KDM4EALDH1A1HPGDNPSR1
SCHEMBL14588690 0.79 CNR1 (0.38) CNR1KDM4EALDH1A1HPGDNPSR1
SCHEMBL4868416 0.79 ALDH1A1 (0.41) CNR1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4863014 0.77 KDM4E (0.37) CNR1KDM4EALDH1A1HPGDNPSR1
SCHEMBL4867441 0.76 CNR1 (0.41) CNR1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL8285503 0.76 TRPA1 (0.47) CNR1KDM4EALDH1A1HPGDNPSR1
SCHEMBL4867176 0.75 NR4A2 (0.41) CNR1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4868951 0.74 SLC6A4 (0.46) CNR1KDM4EALDH1A1HPGDCYP1A2
SCHEMBL4871083 0.74 ALDH1A1 (0.41) KDM4EALDH1A1HPGDHSD17B10TSHR
SCHEMBL24031220 0.74 TARBP2 (0.41) DGAT1KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed